Weight-loss therapy costs set to be lower by up to 90%
NEW DELHI : Weight-loss therapy costs are set to reduce substantially by up to 90%, with generic versions of injectable semaglutide are expected to hit pharmacy shelves from March 21. The move kicks off one of the most closely watched price wars in the high-stakes obesity and diabetes drug market.
This is in the wake of the innovator Novo Nordisk’s patent on semaglutide, the key ingredient in these therapies, expiring on Friday. Two drugmakers including Natco Pharma and Eris Lifesciences announced plans to roll out the pen-filled jabs over 50% cheaper than the innovator’s price, in April. Interestingly, in a bid to lower the therapy cost further, they are also introducing vials at Rs 1,300 per month — about 90% cheaper than the innovator brand Ozempic.
The vial will need to be administered through a syringe by a trained hand. More companies including Sun Pharma, Zydus and Dr Reddy’s are expected to join the highgrowth Rs 1,500 crore therapy market on Day 1 (March 21).
Blockbuster therapies — Wegovy and Mounjaro — marketed by Novo Nordisk and Eli Lilly respectively, were launched at ‘’India-specific prices’’ last year, while global bestseller Ozempic by the Dutch firm, made its India debut in Dec last year. Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, helps to control blood sugar and improve satiety, reducing cravings for food, eventually inducing weight-loss.
Natco plans to launch a semaglutide pen device in April starting at Rs 4,000 per month. The innovator Novo Nordisk’s Ozempic is priced at Rs 8,800 per month for the lowest strength. It is also introducing multi-dose vials starting at Rs 1,290 per month.
Natco said: “It is the most affordable GLP-1 in Indian market as it is around 70% cheaper than pen device, and 90% cheaper than the price of the innovator’s brand. This will increase patient accessibility to the GLP-1 therapy and would help in long term compliance for the patients.”
Ready to Make a Smarter Property Decision? Build Your Legacy with TOI Homes.
Israel Iran War
The vial will need to be administered through a syringe by a trained hand. More companies including Sun Pharma, Zydus and Dr Reddy’s are expected to join the highgrowth Rs 1,500 crore therapy market on Day 1 (March 21).
Blockbuster therapies — Wegovy and Mounjaro — marketed by Novo Nordisk and Eli Lilly respectively, were launched at ‘’India-specific prices’’ last year, while global bestseller Ozempic by the Dutch firm, made its India debut in Dec last year. Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, helps to control blood sugar and improve satiety, reducing cravings for food, eventually inducing weight-loss.
Natco plans to launch a semaglutide pen device in April starting at Rs 4,000 per month. The innovator Novo Nordisk’s Ozempic is priced at Rs 8,800 per month for the lowest strength. It is also introducing multi-dose vials starting at Rs 1,290 per month.
Natco said: “It is the most affordable GLP-1 in Indian market as it is around 70% cheaper than pen device, and 90% cheaper than the price of the innovator’s brand. This will increase patient accessibility to the GLP-1 therapy and would help in long term compliance for the patients.”
Ready to Make a Smarter Property Decision? Build Your Legacy with TOI Homes.
Popular from Business
- No entry: Air India sends 'wrong' Boeing 777 to Canada from Delhi, asks it to return from over China
- An alternative route to Strait of Hormuz? Iran sets up 'corridor', offers ships safe passage for a price
- Airlines vs govt: Air India, IndiGo, SpiceJet oppose Centre's 60 % free seat selection rule, warn of fare hike
- LPG crisis: India turns to US to secure supplies as Strait of Hormuz disruptions continue to bite; shipments rise
- Industrial diesel prices hiked by Rs 22/litre amid Gulf crisis; no change in retail fuel prices
end of article
Trending Stories
- US-Israel-Iran War News Live Updates: Israel pounds Tehran as Iranians mark Nowruz; UAE, Kuwait defences respond to missile barrage
- Florida man loses US citizenship over $3.8 million Covid-19 relief fraud scheme; may face deportation
- ‘Your husband will die’: How Nashik astrologer ‘Captain’ used fear to rape, blackmail woman; pistol, 58 videos found
- Bank holiday today: Are banks closed on March 21, 2026 for Eid-ul-Fitr 2026? Check state-wise list
- 8th Pay Commission salary calculator: Here’s how 8th Pay Commission fitment choices can change your monthly salary
- Industrial diesel prices hiked by Rs 22/litre amid Gulf crisis; no change in retail fuel prices
- No entry: Air India sends 'wrong' Boeing 777 to Canada from Delhi, asks it to return from over China
Featured in Business
- India diversifies LPG supplies, imports 176k tonnes from US
- Premium petrol up Rs 2 per litre amid global oil spike
- $44 billion acquisition: Elon Musk 'misled' Twitter shareholders in 2022, says US jury
- Core sector output slows to 2.3% in February; crude, gas and refinery drag weighs on momentum
- Govt clears Rs 20,000 crore credit guarantee scheme for MFIs; funding access in focus
- Bank holiday today: Are banks closed on March 21, 2026 for Eid-ul-Fitr 2026? Check state-wise list
Photostories
- Men's health: Doctor shares early signs of low testosterone and if over-the-counter supplements help
- From losing his mother at the age of 2 to delivering 15 flop Bhojpuri films and earning Rs 1.5 lakh per episode of Comedy Circus, When Krushna Abhishek opened up about his struggle
- 8 desi vegetables that are actually foreign
- 12 strangest place names in the world and the stories behind them
- Eid Mubarak 2026: 6 traditional Seviyan preparations that complete the Eid feasting
- 5 most scenic riverside retreats in India perfect for April travel
- 5 advanced features in bikes that enhance performance
- Why no one stays in this forest after sunset: Unraveling the mystery of Nidhi Van
- 6 spiritual cities emerging as India’s real estate hotspots in 2026
- 5 ways to use avocado peel in daily meal plans
Up Next
Start a Conversation
Post comment